Payment overview · 2025
General Payments
1 reported records · 1 companies
Healthcare provider profile · identity verified
Allopathic & Osteopathic Physicians|Internal Medicine · NASHVILLE, TN · NPI 1376538207
Verified facts
CMS Open Payments records show Deepinder S Bal, MD received $117.41 in general payments during 2025 across 1 reported records.
Axsome Therapeutics, Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
1 reported records · 1 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $117.41 | 100.0% | 1 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $117.41 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $117.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 390 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 385 | 119 |
| Atorvastatin Calcium | Atorvastatin Calcium | 319 | 95 |
| Pravastatin Sodium | Pravastatin Sodium | 296 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 278 | 85 |
| Telmisartan | Telmisartan | 254 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 221 | 66 |
| Losartan Potassium | Losartan Potassium | 208 | 56 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 200 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 196 | 56 |
| Carvedilol | Carvedilol | 180 | 53 |
| Metformin Hcl Er | Metformin Hcl | 171 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 152 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 139 | 33 |
| Lorazepam | Lorazepam | 134 | 18 |
| Ezetimibe | Ezetimibe | 124 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 111 | 28 |
| Omeprazole | Omeprazole | 108 | 31 |
| Ozempic | Semaglutide | 106 | 28 |
| Diazepam | Diazepam | 103 | 17 |
| Furosemide | Furosemide | 102 | 38 |
| Alprazolam | Alprazolam | 98 | 18 |
| Jardiance | Empagliflozin | 97 | 27 |
| Trazodone Hcl | Trazodone Hcl | 97 | 27 |
| Sertraline Hcl | Sertraline Hcl | 96 | 29 |
| Metformin Hcl | Metformin Hcl | 88 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 14 |
| Clonazepam | Clonazepam | 70 | suppressed |
| Allopurinol | Allopurinol | 68 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 20 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 64 | 14 |
| Pregabalin | Pregabalin | 59 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 17 |
| Irbesartan | Irbesartan | 58 | 15 |
| Lisinopril | Lisinopril | 56 | 19 |
| Tramadol Hcl | Tramadol Hcl | 56 | suppressed |
| Xarelto | Rivaroxaban | 55 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 54 | 15 |
| Famotidine | Famotidine | 53 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 53 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | suppressed |
| Spironolactone | Spironolactone | 51 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 15 |
| Eliquis | Apixaban | 49 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 49 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 46 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 45 | 13 |
| Lovastatin | Lovastatin | 44 | 13 |
| Montelukast Sodium | Montelukast Sodium | 43 | 12 |
| Finasteride | Finasteride | 42 | suppressed |
| Temazepam | Temazepam | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Mirtazapine | Mirtazapine | 40 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 36 | suppressed |
| Nifedipine Er | Nifedipine | 36 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 36 | suppressed |
| Celecoxib | Celecoxib | 35 | 12 |
| Glimepiride | Glimepiride | 34 | 13 |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 30 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | 11 |
| Meloxicam | Meloxicam | 26 | suppressed |
| Potassium Chloride | Potassium Chloride | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Simvastatin | Simvastatin | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Prednisone | Prednisone | 21 | 14 |
| Clonidine | Clonidine | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Jantoven | Warfarin Sodium | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Lipitor | Atorvastatin Calcium | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $117.41 · 1 records | Axsome Therapeutics, Inc. | Auvelity | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error